We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Ampronix,  Inc

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
29 Aug 2020 - 02 Sep 2020
Virtual Venue

Illustration

BioMérieux SARS-CoV-2 Serology Tests Granted FDA Emergency Use Authorization

BioMérieux’s (Marcy-l'Étoile, France) has been granted Emergency Use Authorizations (EUAs) by the US Food and Drug Administration (FDA) for two SARS-CoV-2 serology tests. More...
11 Aug 2020
Illustration

NIH Begins Clinical Trial of Antiviral Remdesivir Plus Immunomodulator Interferon Beta-1a in COVID-19 Patients

The National Institutes of Health (NIH Bethesda, MA, USA) has begun a randomized, controlled clinical trial evaluating the safety and efficacy of a treatment regimen consisting of the antiviral remdesivir plus the immunomodulator interferon beta-1a in COVID-19 patients. More...
11 Aug 2020
Illustration

Pfizer Enters Into Multi-Year Agreement with Gilead to Manufacture Investigational Antiviral Remdesivir for COVID-19

Pfizer Inc. (New York, NY, USA) has entered into a multi-year agreement with Gilead Sciences (Foster City, CA, USA) to manufacture and supply Gilead’s investigational COVID-19 treatment remdesivir. More...
11 Aug 2020
Illustration

AstraZeneca Signs Licensing Deal with China’s BioKangtai for 100 Million Doses of Oxford COVID-19 Vaccine by Year End

AstraZeneca (Cambridgeshire, England) has signed a licensing deal with Chinese firm BioKangtai (Guangdong, Chin) to supply its adenovirus vector-based COVID-19 vaccine candidate, AZD1222, developed by the University of Oxford (Oxford, UK), to China. More...
11 Aug 2020
Illustration

Human Trial of Pill That Could Reduce COVID-19 Related Lung Damage Begins At First US Clinical Trial Site

Ifenprodil, a drug in pill form repurposed by Algernon Pharmaceuticals (Vancouver, BC, Canada) to treat COVID-19 damage in the lungs, is being tested as a possible treatment on coronavirus patients for the first time in the US. More...
11 Aug 2020
World Health Organization

No 'Silver Bullet' for COVID-19, Widespread Vaccine Distribution Unlikely To Occur For Some Time, Says WHO

The World Health Organization (WHO Geneva, Switzerland) has warned that although a number of COVID-19 vaccines are now in Phase 3 clinical trials, no silver bullet presently exists and there may never be one. More...
10 Aug 2020
Illustration

Antibodies Disappear in 10% of Coronavirus-Recovered Patients and 5% Test Positive Again In New Study

A study has revealed that antibodies against the novel coronavirus disappeared in 10% of a sample group of COVID-19-recovered patients, 5% were again in quarantine after testing positive for the virus, and 90% reported lung damage. More...
10 Aug 2020
Copyright © 2000-2020 Globetech Media. All rights reserved.